| Website | amuletpharma.com |
| Category | BioTech |
| info@amuletpharma... | |
| Employees |
| TOTAL | $1.7M |
| FUNDING TOTAL | $1.7M |
| Series A, 3/07 Wilmington Investor Network Springboard Capital | $1.7M |
Amulet Pharmaceuticals discovers and develops novel therapeutics using their NORTECHâ„¢ technology to address known liabilities of current therapies serving large unmet markets. Their lead program (AMU-301) treats diabetic gastroparesis an unmet complication of diabetes affecting over 3 million women in the United States.
